These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26806790)

  • 21. Comparative efficacy and tolerability of antiemetic prophylaxis for adult highly emetogenic chemotherapy: A network meta-analysis of 143 randomized controlled trials.
    Cheng J; Cai M; Shuai X; Gao J; Wang G; Tao K
    Int J Cancer; 2018 Mar; 142(5):1067-1076. PubMed ID: 29055118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
    Raftopoulos H; Boccia R; Cooper W; O'Boyle E; Gralla RJ
    Future Oncol; 2015 Sep; 11(18):2541-51. PubMed ID: 26289588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
    Trigg ME; Inverso DM
    Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types.
    Aapro MS; Schmoll HJ; Jahn F; Carides AD; Webb RT
    Cancer Treat Rev; 2013 Feb; 39(1):113-7. PubMed ID: 23062719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurokinin-1-receptor antagonists: a new approach in antiemetic therapy.
    Jordan K
    Onkologie; 2006 Feb; 29(1-2):39-43. PubMed ID: 16514255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis.
    Zhang Y; Hou X; Zhang R; Chen G; Huang Y; Yang Y; Zhao Y; Fang W; Hong S; Kang S; Zhou T; Zhang Z; Chen X; Zhang L
    Future Oncol; 2018 Aug; 14(19):1933-1941. PubMed ID: 30019968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.
    Fonte C; Fatigoni S; Roila F
    Crit Rev Oncol Hematol; 2015 Aug; 95(2):214-21. PubMed ID: 25779971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Incidence and treatment of chemotherapy-induced nausea and emesis in gastrointestinal cancer].
    Lorenzen S; Spörl S; Lordick F
    Z Gastroenterol; 2014 Aug; 52(8):821-30. PubMed ID: 25111723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.
    Mizukami N; Yamauchi M; Koike K; Watanabe A; Ichihara K; Masumori N; Yamakage M
    J Pain Symptom Manage; 2014 Mar; 47(3):542-50. PubMed ID: 23856100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES
    Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoids in Patients with Nausea and Vomiting Associated with Malignancy and Its Treatments.
    Garcia JM; Shamliyan TA
    Am J Med; 2018 Jul; 131(7):755-759.e2. PubMed ID: 29909841
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
    Song HJ; Seo HJ; Son H
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1289-1301. PubMed ID: 27526189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only).
    Roila F; Warr D; Aapro M; Clark-Snow RA; Einhorn L; Gralla RJ; Herrstedt J; Saito M; Tonato M
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S57-62. PubMed ID: 21132332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.
    Chapell R; Aapro MS
    J Geriatr Oncol; 2013 Jan; 4(1):78-83. PubMed ID: 24071495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.